{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,10,10]],"date-time":"2024-10-10T12:40:17Z","timestamp":1728564017276},"reference-count":56,"publisher":"Informa UK Limited","issue":"6","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Biological Therapy"],"published-print":{"date-parts":[[2024,6,2]]},"DOI":"10.1080\/14712598.2024.2365802","type":"journal-article","created":{"date-parts":[[2024,6,11]],"date-time":"2024-06-11T17:26:27Z","timestamp":1718126787000},"page":"415-423","update-policy":"http:\/\/dx.doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["An evaluation of nadofaragene firadenovec-vncg for the treatment of high-risk BCG-unresponsive non-muscle-invasive bladder cancer"],"prefix":"10.1080","volume":"24","author":[{"given":"Zine-Eddine","family":"Khene","sequence":"first","affiliation":[{"name":"Department of Urology, UT Southwestern Medical Center, Dallas, TX, USA"},{"name":"Department of Urology, Rennes University Hospital, Rennes, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yair","family":"Lotan","sequence":"additional","affiliation":[{"name":"Department of Urology, UT Southwestern Medical Center, Dallas, TX, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2024,6,13]]},"reference":[{"key":"e_1_3_5_3_1","unstructured":"Bladder cancer: non-muscle invasive guideline - American urological association. n.d [cited 2023 Dec 26]. Available from: https:\/\/www.auanet.org\/guidelines-and-quality\/guidelines\/bladder-cancer-non-muscle-invasive-guideline"},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000000593"},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2020.04.066"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.suronc.2016.05.027"},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euros.2022.12.016"},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrurol.2017.16"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)67799-3"},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00147-9"},{"key":"e_1_3_5_11_1","unstructured":"Commissioner O of the. FDA approves first gene therapy for the treatment of high-risk non-muscle-invasive bladder cancer. FDA; 2022 [cited 2023 Dec 26]. Available from: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-gene-therapy-treatment-high-risk-non-muscle-invasive-bladder-cancer"},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2005.08.066"},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.3233\/BLC-159002"},{"key":"e_1_3_5_14_1","unstructured":"Research C for DE and. Bacillus calmette-gu\u00e9rin-unresponsive nonmuscle invasive bladder cancer: developing drugs and biologics for treatment guidance for industry 2020. [cited 2023 Dec 26]. Available from: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/bacillus-calmette-guerin-unresponsive-nonmuscle-invasive-bladder-cancer-developing-drugs-and"},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.0954-6820.1978.tb08475.x"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2013.02.010"},{"key":"e_1_3_5_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2005.11.026"},{"key":"e_1_3_5_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012112.pub2"},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(01)63160-4"},{"key":"e_1_3_5_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2004.05.027"},{"key":"e_1_3_5_21_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.8493530"},{"key":"e_1_3_5_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.gene.2013.03.137"},{"key":"e_1_3_5_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ucl.2019.09.011"},{"key":"e_1_3_5_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.cgt.7700364"},{"key":"e_1_3_5_25_1","doi-asserted-by":"publisher","DOI":"10.5301\/uro.5000184"},{"key":"e_1_3_5_26_1","first-page":"493","article-title":"Bladder surface glycosaminoglycans is a human epithelial permeability barrier","volume":"171","author":"Lilly JD","year":"1990","unstructured":"Lilly JD, Parsons CL. Bladder surface glycosaminoglycans is a human epithelial permeability barrier. Surg Gynecol Obstet. 1990;171:493\u2013496.","journal-title":"Surg Gynecol Obstet"},{"key":"e_1_3_5_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(01)62968-9"},{"key":"e_1_3_5_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0090-4295(98)00641-4"},{"key":"e_1_3_5_29_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.gt.3301348"},{"key":"e_1_3_5_30_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.cgt.7700488"},{"key":"e_1_3_5_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2004.05.027"},{"key":"e_1_3_5_32_1","doi-asserted-by":"publisher","DOI":"10.4161\/cbt.6.6.4088"},{"key":"e_1_3_5_33_1","first-page":"808","article-title":"Inhibition of basic fibroblast growth factor expression, angiogenesis, and growth of human bladder carcinoma in mice by systemic interferon-alpha administration","volume":"58","author":"Dinney CP","year":"1998","unstructured":"Dinney CP, Bielenberg DR, Perrotte P, et al. Inhibition of basic fibroblast growth factor expression, angiogenesis, and growth of human bladder carcinoma in mice by systemic interferon-alpha administration. Cancer Res. 1998;58:808\u2013814.","journal-title":"Cancer Res"},{"key":"e_1_3_5_34_1","first-page":"1258","article-title":"Inhibition of tumorigenicity and metastasis of human bladder cancer growing in athymic mice by interferon-beta gene therapy results partially from various antiangiogenic effects including endothelial cell apoptosis","volume":"8","author":"Izawa JI","year":"2002","unstructured":"Izawa JI, Sweeney P, Perrotte P, et al. Inhibition of tumorigenicity and metastasis of human bladder cancer growing in athymic mice by interferon-beta gene therapy results partially from various antiangiogenic effects including endothelial cell apoptosis. Clin Cancer Res. 2002;8:1258\u20131270.","journal-title":"Clin Cancer Res"},{"key":"e_1_3_5_35_1","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2019.1577125"},{"key":"e_1_3_5_36_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20101158"},{"key":"e_1_3_5_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2013.03.030"},{"key":"e_1_3_5_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2021.12.009"},{"key":"e_1_3_5_39_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.72.3064"},{"key":"e_1_3_5_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30540-4"},{"key":"e_1_3_5_41_1","unstructured":"Society of urologic oncology - efficacy of intravesical nadofaragene firadenovec for patients with BCG-unresponsive carcinoma in situ of the bladder: 36-month follow-up from a phase 3 trial. n.d [cited 2023 Dec 31]. Available from: https:\/\/suo-abstracts.secureplatform.com\/a\/gallery\/rounds\/18\/details\/2938"},{"key":"e_1_3_5_42_1","unstructured":"Ferring Pharmaceuticals. A phase 3 open label trial to evaluate the safety and efficacy of FE 999326 administered intravesically to Japanese subjects with high-grade BCG unresponsive non-muscle invasive bladder cancer (NMIBC). clinicaltrials. gov; 2023."},{"key":"e_1_3_5_43_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2022.0041"},{"key":"e_1_3_5_44_1","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000000688"},{"key":"e_1_3_5_45_1","doi-asserted-by":"publisher","DOI":"10.1111\/bju.16087"},{"key":"e_1_3_5_46_1","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2200167"},{"key":"e_1_3_5_47_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.6_suppl.TPS598"},{"key":"e_1_3_5_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2017.07.005"},{"key":"e_1_3_5_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.10.111"},{"key":"e_1_3_5_50_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1040669"},{"key":"e_1_3_5_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2022.02.009"},{"key":"e_1_3_5_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2012.07.097"},{"key":"e_1_3_5_53_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.4597"},{"key":"e_1_3_5_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.omto.2022.06.005"},{"key":"e_1_3_5_55_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.4_suppl.LBA531"},{"key":"e_1_3_5_56_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-2158"},{"key":"e_1_3_5_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2022.05.016"},{"key":"e_1_3_5_58_1","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics12030586"}],"container-title":["Expert Opinion on Biological Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14712598.2024.2365802","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,10]],"date-time":"2024-10-10T11:54:53Z","timestamp":1728561293000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14712598.2024.2365802"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,2]]},"references-count":56,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6,2]]}},"alternative-id":["10.1080\/14712598.2024.2365802"],"URL":"https:\/\/doi.org\/10.1080\/14712598.2024.2365802","relation":{},"ISSN":["1471-2598","1744-7682"],"issn-type":[{"type":"print","value":"1471-2598"},{"type":"electronic","value":"1744-7682"}],"subject":[],"published":{"date-parts":[[2024,6,2]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iebt20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iebt20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2024-01-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-06-05","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-06-13","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}